Traditional Chinese medicine production enterprises face authentication key period 
 
 
http://www.pharmacy.hc360.com 
 
 
On December 27, 2014, over 
 
 
Source: China pharmaceutical network 

    Takeaway: automobil pharmaceutical industry network 】 【 according to the demand of the CFDA to December 31, 2015, all kinds of pharmaceutical production enterprise, should conform to the 2010 version of the GMP requirements, otherwise, they need to stop business operations for rectification. According to according to the November 20, 2014, the number of Chinese pharmaceutical enterprises. 2010 version of the GMP certificate for 4130 (including non sterile sterile pharmaceutical companies and pharmaceutical companies). 
 
    Estimated for the total number of national pharmaceutical enterprise in about 6000, less than 70% pass rate. Many traditional Chinese medicine production enterprises are also facing a critical period of certification, the enterprise will be invested heavily busy certification, will affect the production and purchase quantity will decrease accordingly.
 
    After five years of efforts, the new pharmacopoeia in 2015 is expected to be promulgated in the second half of the year. Although the new pharmacopoeia will of traditional Chinese medicine (TCM), included increased, but on the whole to further enhance the drug quality control, especially control project on the safety of Chinese medicine varieties, such as traditional Chinese medicine and yinpian sulfur dioxide residue limits standard, heavy metals and harmful elements, aflatoxin and the measure of materials such as pesticide residue detection. The improvement of quality standards will also increase in the process of Chinese herbal medicine planting, processing and production cost, drug procurement standard so will improve, does not comply with the pharmacopoeia standards of Chinese medicinal materials sales will be difficult.
 
    Chinese herbal medicine production in 2015 is likely to scale down, but not too much. 2014 most what medicinal material prices falling, but in addition to the individual breed at a loss, basic on the cost price, farmers still profits, not greatly lowered. And in recent years, the planting base, cooperative, etc., with the support from nation to nation, also will choose medicinal plant. Overall acreage greatly lowered is unlikely.
 
    In 2015, the situation is still grim, Chinese traditional medicine is no business? As long as the heart still can find business opportunities in the difficult. On November 3, 2014 German bayer group completed the yunnan hong pharmaceutical group co., LTD. All shares. Rainbow is a major production of yunnan dermatologist over-the-counter medications (OTC) and for the treatment of various gynecological diseases of traditional Chinese herbal medicine product of private pharmaceutical companies, the acquisition shows that traditional Chinese medicine increasingly brought to the attention of the domestic and foreign pharmaceutical companies, countries are actively encouraging support domestic Chinese medicine research and development of enterprise innovation, which will promote Chinese medicine sales increase.
 
    Development and reform commission (NDRC) recently proposed release drug prices, medical insurance drugs price scheme or monthly notices of the state council for examination and approval, November is expected in 2015, it will be good for proprietary Chinese medicine production, because of proprietary Chinese medicine raw materials price change with market supply and demand of Chinese medicinal materials, but the price of proprietary Chinese medicine cannot adjust, restricted the proprietary Chinese medicine production, lead to some low medicine disappear in the market.